Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 12Gastrointestinal 5NET 3Genitourinary 3Dermatologic 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Pituitary Neoplasms 1Neuroectodermal Tumors, Primitive 1Nelson Syndrome 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1ACTH Syndrome, Ectopic 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 142Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × pasireotide × Gastrointestinal × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT01639352 2017-07-12

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

University of Miami

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT01488487 2016-04-07

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
24 enrolled 17 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00994110 2016-02-01

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
439 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡